GSK posts higher profits but indicates sales growth to slow in 2026 - It came amid the first set of results by new chief ...

GSK beat profit expectations in the fourth quarter, driven by demand for its HIV drugs and Asthma medicine.

Its adjusted earnings per share rises to 25.5 pence, higher than analysts’ expectations Read more at The Business Times.

Pharmaceutical giant GSK has revealed a jump in profits amid a boost from HIV and asthma treatments, but pointed towards ...

LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...

The UK's FTSE 100 closed at a record high due to a boost from healthcare stocks, led by GSK's impressive earnings. The FTSE ...

GSK posted higher profit as sales for its specialty treatments including HIV, cancer and asthma beat expectations, offsetting lower vaccine sales on weak demand in the U.S. GSK plans to bring five new ...

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market this ...